JP Morgan Upgrades Ariad Pharmaceuticals (ARIA) to Overweight
More News related to ARIA
- ARIAD to Present at the 12th Annual BIO CEO & Investor Conference
- Ariad Pharma (ARIA) Files $125M Mixed Shelf
- ARIAD to Present at the 28th Annual J.P. Morgan Healthcare Conference
- ARIAD Pharma (ARIA) Completes Enrollment for Ridaforolimus Phase 3
- ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
More News related to Trader Talk
- S&P Announces Change to US Index: TSRA for FIF
- Baidu (BIDU) is up about $35 or 8% following a blow-out Q4
- Morgan Stanley Says Buy Commodities on Recent Dip
- Germany is considering loan guarantees for Greece and other troubled euro partners - WSJ
- Sprint (S): Q4 Earnings Preview
JP Morgan upgrades Ariad Pharmaceuticals Inc. (Nasdaq: ARIA) Neutral to Overweight with a $6 price target.
ARIAD Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer in the United States and Europe.
Related Categories
Trader TalkUpgrades
Stocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
